Asset profile
Cannabidiol (Epidiolex)
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Epilepsy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
62 competitors in this universe: 1 direct rival (same mechanism and indication), 1 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Cannabidiol (Epidiolex): this drug | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | ||
| JZP926 | Phase 3 | Small molecule | Cannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoid | ||
| Cannabidiol (Kanbis) | Phase 2 | Small molecule | cannabinoid | ||
| Brivaracetam | Approved | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | ||
| Carbamazepine | Approved | Small molecule | Sodium channels | ||
| Cenobamate (Xcopri) | Approved | Small molecule | Sodium channels + GABA-A receptors | ||
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | ||
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | ||
| Diastat | Approved | Combination | GABA-A receptor | ||
| Diazepam (Valium) | Approved | Small molecule | GABA-A receptor | ||
| Diazepam (Valtoco) | Approved | Small molecule | GABA-A receptor | ||
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | ||
| Eslicarbazepine Acetate (Aptiom) | Approved | Small molecule | Voltage-gated sodium channel | ||
| Ethosuximide | Approved | Small molecule | T-type calcium channel | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | ||
| Ezogabine (Potiga) | Approved | Small molecule | Kv7 potassium channel |
…and 47 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(70 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (15)
November 2026 (1)
Phase 2Chronic PainActive not recruiting
Est. primary completion 2026-11 · NCT03984565 · CT.gov ↗
What to watch
December 2026 (14)
Phase 1Autism Spectrum DisorderRecruiting
Est. primary completion 2026-12 · NCT05015439 · CT.gov ↗
What to watch
Phase 2Bipolar DisorderRecruiting
Est. primary completion 2026-12 · NCT05457465 · CT.gov ↗
What to watch
Phase 2EndometriosisActive not recruiting
Est. primary completion 2026-12 · NCT06477406 · CT.gov ↗
What to watch
Early phase / not applicableCannabis IntoxicationNot yet recruiting
Est. primary completion 2026-12 · NCT07471347 · CT.gov ↗
What to watch
Phase 1Burnout SyndromeNot yet recruiting
Est. primary completion 2026-12-01 · NCT06617247 · CT.gov ↗
What to watch
Phase 1Tobacco Use, Tobacco Smoking, Tobacco Dependence, Tobacco Use Disorder, Tobacco Use CessationRecruiting
Est. primary completion 2026-12-01 · NCT05445804 · CT.gov ↗
What to watch
Phase 2Carpal Tunnel SyndromeNot yet recruiting
Est. primary completion 2026-12-01 · NCT06108349 · CT.gov ↗
What to watch
Phase 2Alzheimer DiseaseRecruiting
Est. primary completion 2026-12-29 · NCT06014424 · CT.gov ↗
What to watch
Phase 1Anxiety and FearRecruiting
Est. primary completion 2026-12-30 · NCT05283382 · CT.gov ↗
What to watch
Phase 1/2Shoulder Osteoarthritis, Rotator Cuff InjuriesRecruiting
Est. primary completion 2026-12-30 · NCT06381791 · CT.gov ↗
What to watch
Phase 1Drug Drug InteractionNot yet recruiting
Est. primary completion 2026-12-31 · NCT07462559 · CT.gov ↗
What to watch
Phase 1/2Osteoarthritis, KneeRecruiting
Est. primary completion 2026-12-31 · NCT06414473 · CT.gov ↗
What to watch
Phase 2Anxiety, Generalized Anxiety Disorder, Sleep ProblemsActive not recruiting
Est. primary completion 2026-12-31 · NCT06672666 · CT.gov ↗
What to watch
Phase 2Tobacco Use Disorder, Tobacco Smoking, Tobacco DependenceRecruiting
Est. primary completion 2026-12-31 · NCT06218056 · CT.gov ↗
What to watch
2027 (24)
February 2027 (1)
Phase 1/2Sickle Cell DiseaseRecruiting
Est. primary completion 2027-02-01 · NCT06930703 · CT.gov ↗
What to watch
March 2027 (2)
April 2027 (2)
May 2027 (1)
Phase 4Phobia, SocialRecruiting
Est. primary completion 2027-05 · NCT05649059 · CT.gov ↗
What to watch
June 2027 (1)
July 2027 (3)
Early phase / not applicableWell-Being, Psychological, Quality of Life, Sexual Behavior, Sexual Pain DisorderRecruiting
Est. primary completion 2027-07 · NCT07271030 · CT.gov ↗
What to watch
Phase 3Opioid Use Disorder (OUD)Recruiting
Est. primary completion 2027-07-15 · NCT06940674 · CT.gov ↗
What to watch
Phase 2Persistent Post Traumatic HeadacheNot yet recruiting
Est. primary completion 2027-07-31 · NCT07624279 · CT.gov ↗
What to watch
August 2027 (4)
Phase 2Chronic Pruritus, Eczema, Nummular Eczema, Atopic Dermatitis, Prurigo NodularisEnrolling by invitation
Est. primary completion 2027-08-01 · NCT06994520 · CT.gov ↗
What to watch
Phase 4EpilepsyActive not recruiting
Est. primary completion 2027-08-01 · NCT05044819 · CT.gov ↗
What to watch
Phase 1InteractionRecruiting
Est. primary completion 2027-08-31 · NCT06692933 · CT.gov ↗
What to watch
Phase 3Generalized Anxiety Disorder (GAD), Anxiety DisordersRecruiting
Est. primary completion 2027-08-31 · NCT07123467 · CT.gov ↗
What to watch
September 2027 (3)
Phase 2/3Knee ArthritisRecruiting
Est. primary completion 2027-09 · NCT05020028 · CT.gov ↗
What to watch
Phase 1Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Metastatic Colorectal Cancer (CRC), Peripheral Neuropathy Due to ChemotherapyRecruiting
Est. primary completion 2027-09-05 · NCT07167446 · CT.gov ↗
What to watch
Phase 3InsomniaActive not recruiting
Est. primary completion 2027-09-30 · NCT05840822 · CT.gov ↗
What to watch
October 2027 (2)
November 2027 (1)
December 2027 (4)
Phase 1Forehead; WoundNot yet recruiting
Est. primary completion 2027-12 · NCT05650697 · CT.gov ↗
What to watch
Phase 2SchizophreniaActive not recruiting
Est. primary completion 2027-12 · NCT02926859 · CT.gov ↗
What to watch
Phase 3Mediciine, Systemic Sclerosis (SSc), Intervention StudyRecruiting
Est. primary completion 2027-12 · NCT07245238 · CT.gov ↗
What to watch
Early phase / not applicableCBD, Cannabidiol, Stress, Acute Stress ReactionRecruiting
Est. primary completion 2027-12-31 · NCT07069478 · CT.gov ↗
What to watch
2028 (20)
January 2028 (2)
March 2028 (2)
April 2028 (2)
May 2028 (4)
Phase 2Supra-sacral Spinal Cord Injury, Spinal Cord Injury, Urinary IncontinenceRecruiting
Est. primary completion 2028-05 · NCT06840899 · CT.gov ↗
What to watch
Phase 3Opioid Use DisorderNot yet recruiting
Est. primary completion 2028-05 · NCT07148206 · CT.gov ↗
What to watch
Phase 2Sleep, Anxiety, Depression, PainRecruiting
Est. primary completion 2028-05-30 · NCT06266611 · CT.gov ↗
What to watch
Phase 2Metastatic Castration Resistant Prostate Cancer (mCRPC)Recruiting
Est. primary completion 2028-05-31 · NCT07549256 · CT.gov ↗
What to watch
June 2028 (2)
July 2028 (3)
Phase 2Sturge - Weber Syndrome (SWS)Recruiting
Est. primary completion 2028-07 · NCT07778810 · CT.gov ↗
What to watch
Phase 2Fragile X SyndromeRecruiting
Est. primary completion 2028-07-01 · NCT06261502 · CT.gov ↗
What to watch
Phase 1/2Cannabis Use DisorderRecruiting
Est. primary completion 2028-07-31 · NCT05885542 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Sleep, Anxiety, Depression, PainRecruiting
Est. primary completion 2028-08-31 · NCT06290063 · CT.gov ↗
What to watch
December 2028 (4)
Phase 4EpilepsyNot yet recruiting
Est. primary completion 2028-12-28 · NCT07728097 · CT.gov ↗
What to watch
Phase 1Cannabidiol Effects, Driving PerformanceRecruiting
Est. primary completion 2028-12-31 · NCT06686914 · CT.gov ↗
What to watch
2029 (6)
January 2029 (1)
Phase 2Knee Replacement Surgery, Osteoarthritis, KneeRecruiting
Est. primary completion 2029-01 · NCT06234631 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Neurodevelopmental Disorders With Severe Self-injuriesNot yet recruiting
Est. primary completion 2029-05 · NCT07564245 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Alcohol Use DisorderRecruiting
Est. primary completion 2029-08-31 · NCT07279558 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1CBD, Stress, Nicotine Dependence, Tobacco SmokingRecruiting
Est. primary completion 2029-09-01 · NCT07001930 · CT.gov ↗
What to watch
2030 (3)
February 2030 (1)
Phase 1/2Early Life Adversity, Trauma, StressRecruiting
Est. primary completion 2030-02-28 · NCT07278505 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2/3Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification, CravingRecruiting
Est. primary completion 2030-10-31 · NCT07148843 · CT.gov ↗
What to watch
December 2030 (1)
Phase 1/2Post Traumatic Stress Disorder, Cannabis Use, Suicide, Veterans, MarijuanaRecruiting
Est. primary completion 2030-12-31 · NCT06381180 · CT.gov ↗
What to watch
2031 (2)
February 2031 (1)
Phase 2Sleep, Alcohol MisuseNot yet recruiting
Est. primary completion 2031-02-01 · NCT07527338 · CT.gov ↗
What to watch
September 2031 (1)
Phase 1/2PTSD, Post Traumatic Stress Disorder, Suicide, Cannabis UseNot yet recruiting
Est. primary completion 2031-09 · NCT06222268 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.